Strategies to increase nitric oxide signalling in cardiovascular disease

Nature Reviews Drug Discovery

Volumn 14, Issue 9, 2015, Pages 623-641

  Lundberg, Jon O ^a   Gladwin, Mark T ^b   Weitzberg, Eddie ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALCOHOL; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ARGINASE; ARGININE; CITRULLINE; CORTICOSTEROID; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FATTY ACID DERIVATIVE; GUANYLATE CYCLASE; GUANYLATE CYCLASE ACTIVATOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; N(G),N(G) DIMETHYLARGININE; NEBIVOLOL; NITRATE; NITRATED FATTY ACID; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE INHIBITOR; NITRITE; POLYPHENOL; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; TETRAHYDROBIOPTERIN; UNCLASSIFIED DRUG;

ACUTE HEART INFARCTION; ATHEROSCLEROSIS; BIOAVAILABILITY; CARDIOVASCULAR DISEASE; DIET SUPPLEMENTATION; DIET THERAPY; DRUG HALF LIFE; DRUG TARGETING; ENZYME INHIBITION; HEART FAILURE; HEART PROTECTION; HUMAN; HYPERTENSION; INTRACELLULAR SIGNALING; KINESIOTHERAPY; NONHUMAN; OXIDATION REDUCTION STATE; OXIDATIVE STRESS; PARACRINE SIGNALING; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PULMONARY HYPERTENSION; PULMONARY VASCULAR DISEASE; REVIEW; TREATMENT OUTCOME; ANIMAL; CARDIOVASCULAR DISEASES; METABOLISM; PHYSIOLOGY; RISK REDUCTION; SIGNAL TRANSDUCTION;

ANIMALS; CARDIOVASCULAR DISEASES; HUMANS; NITRIC OXIDE; REACTIVE OXYGEN SPECIES; RISK REDUCTION BEHAVIOR; SIGNAL TRANSDUCTION;

EID: 84940893043     PISSN: 14741776     EISSN: 14741784     Source Type: Journal    
DOI: 10.1038/nrd4623     Document Type: Review

References (265)

1. Forstermann, U. & Munzel, T. Endothelial nitric oxide synthase in vascular disease: from marvel to menace. Circulation 113, 1708-1714 (2006).
2. Arnold, W. P., Mittal, C. K., Katsuki, S. & Murad, F. Nitric oxide activates guanylate cyclase and increases guanosine 3′:5′-cyclic monophosphate levels in various tissue preparations. Proc. Natl Acad. Sci. USA 74, 3203-3207 (1977).
3. Katsuki, S., Arnold, W., Mittal, C. & Murad, F. Stimulation of guanylate cyclase by sodium nitroprusside, nitroglycerin and nitric oxide in various tissue preparations and comparison to the effects of sodium azide and hydroxylamine. J. Cyclic Nucleotide Res. 3, 23-35 (1977).
4. Furchgott, R. F. & Zawadzki, J. V. The obligatory role of the endothelium in the relaxation of arterial smooth muscle by acetylcholine. Nature 288, 373-376 (1980).
5. Ignarro, L. J., Buga, G. M., Wood, K. S., Byrns, R. E. & Chaudhuri, G. Endothelium-derived relaxing factor produced and released from artery and vein is nitric oxide. Proc. Natl Acad. Sci. USA 84, 9265-9269 (1987).
6. Palmer, R. M., Ferrige, A. G. & Moncada, S. Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor. Nature 327, 524-526 (1987).
7. Ghofrani, H. A., Osterloh, I. H. & Grimminger, F. Sildenafil: from angina to erectile dysfunction to pulmonary hypertension and beyond. Nat. Rev. Drug Discov. 5, 689-702 (2006).
8. Frostell, C., Fratacci, M. D., Wain, J. C., Jones, R. & Zapol, W. M. Inhaled nitric oxide. A selective pulmonary vasodilator reversing hypoxic pulmonary vasoconstriction. Circulation 83, 2038-2047 (1991).
9. Kinsella, J. P. et al. Early inhaled nitric oxide therapy in premature newborns with respiratory failure. N. Engl. J. Med. 355, 354-364 (2006).
10. Munzel, T., Daiber, A. & Mulsch, A. Explaining the phenomenon of nitrate tolerance. Circ. Res. 97, 618-628 (2005).
11. Lundberg, J. O., Feelisch, M., Bjorne, H., Jansson, E. A. & Weitzberg, E. Cardioprotective effects of vegetables: is nitrate the answer? Nitric Oxide 15, 359-362 (2006).
12. Classen, H. G., Stein-Hammer, C. & Thoni, H. Hypothesis: the effect of oral nitrite on blood pressure in the spontaneously hypertensive rat. Does dietary nitrate mitigate hypertension after conversion to nitrite? J. Am. Coll. Nutr. 9, 500-502 (1990).
13. Moncada, S., Palmer, R. M. J. & Higgs, E. A. Nitric oxide: physiology, pathophysiology, and pharmacology. Pharmacol. Rev. 43, 109-141 (1991).
14. Forstermann, U. & Sessa, W. C. Nitric oxide synthases: regulation and function. Eur. Heart J. 33, 829-837 (2012).
15. Dimmeler, S. et al. Activation of nitric oxide synthase in endothelial cells by Akt-dependent phosphorylation. Nature 399, 601-605 (1999).
16. Fulton, D. et al. Regulation of endothelium-derived nitric oxide production by the protein kinase Akt. Nature 399, 597-601 (1999).
17. Tayeh, M. A. & Marletta, M. A. Macrophage oxidation of l-arginine to nitric oxide, nitrite, and nitrate. Tetrahydrobiopterin is required as a cofactor. J. Biol. Chem. 264, 19654-19658 (1989).
18. Landmesser, U. et al. Oxidation of tetrahydrobiopterin leads to uncoupling of endothelial cell nitric oxide synthase in hypertension. J. Clin. Invest. 111, 1201-1209 (2003).
19. Szabo, C., Ischiropoulos, H. & Radi, R. Peroxynitrite: biochemistry, pathophysiology and development of therapeutics. Nat. Rev. Drug Discov. 6, 662-680 (2007).
20. Nathan, C. Inducible nitric oxide synthase: what difference does it make? J. Clin. Invest. 100, 2417-2423 (1997).
21. Lundberg, J. O. et al. High nitric oxide production in human paranasal sinuses. Nat. Med. 1, 370-373 (1995).
22. Lowry, J. L., Brovkovych, V., Zhang, Y. & Skidgel, R. A. Endothelial nitric-oxide synthase activation generates an inducible nitric-oxide synthase-like output of nitric oxide in inflamed endothelium. J. Biol. Chem. 288, 4174-4193 (2013).
23. Lundberg, J. O., Weitzberg, E. & Gladwin, M. T. The nitrate-nitrite-nitric oxide pathway in physiology and therapeutics. Nat. Rev. Drug Discov. 7, 156-167 (2008).
24. Lundberg, J. O. et al. Nitrate and nitrite in biology, nutrition and therapeutics. Nat. Chem. Biol. 5, 865-869 (2009).
25. van Faassen, E. E. et al. Nitrite as regulator of hypoxic signaling in mammalian physiology. Med. Res. Rev. 29, 683-741 (2009).
26. Kim-Shapiro, D. B. & Gladwin, M. T. Pitfalls in measuring NO bioavailability using NOx. Nitric Oxide 44, 1-2 (2014).
27. Weitzberg, E. & Lundberg, J. O. Novel aspects of dietary nitrate and human health. Annu. Rev. Nutr. 33, 129-159 (2013).
28. Lundberg, J. O., Weitzberg, E., Cole, J. A. & Benjamin, N. Nitrate, bacteria and human health. Nat. Rev. Microbiol. 2, 593-602 (2004).
29. Jansson, E. A. et al. A mammalian functional nitrate reductase that regulates nitrite and nitric oxide homeostasis. Nat. Chem. Biol. 4, 411-417 (2008).
30. Spiegelhalder, B., Eisenbrand, G. & Preussman, R. Influence of dietary nitrate on nitrite content of human saliva: possible relevance to in vivo formation of N-nitroso compounds. Food Cosmet. Toxicol. 14, 545-548 (1976).
31. Lundberg, J. O. Nitrate transport in salivary glands with implications for NO homeostasis. Proc. Natl Acad. Sci. USA 109, 13144-13145 (2012).
32. Qin, L. et al. Sialin (SLC17A5) functions as a nitrate transporter in the plasma membrane. Proc. Natl Acad. Sci. USA 109, 13434-13439 (2012).
33. Lundberg, J. O. & Govoni, M. Inorganic nitrate is a possible source for systemic generation of nitric oxide. Free Radic. Biol. Med. 37, 395-400 (2004).
34. Carlstrom, M. et al. Cross-talk between nitrate- nitrite-NO and NO synthase pathways in control of vascular NO homeostasis. Antioxid. Redox Signal. http://dx.doi.org/10.1089/ars.2013.5481 (2014).
35. Larsen, F. J., Ekblom, B., Sahlin, K., Lundberg, J. O. & Weitzberg, E. Effects of dietary nitrate on blood pressure in healthy volunteers. N. Engl. J. Med. 355, 2792-2793 (2006).
36. Omar, S. A. et al. Paradoxical normoxia-dependent selective actions of inorganic nitrite in human muscular conduit arteries and related selective actions on central blood pressures. Circulation 131, 381-389 (2015).
37. Beckman, J. S., Beckman, T. W., Chen, J., Marshall, P. & Freeman, B. A. Apparent hydroxyl radical production by peroxinitrite: implications for endothelial cell injury from nitric oxide. Proc. Natl Acad. Sci. USA 87, 1620-1624 (1990).
38. Gow, A. J., Farkouh, C. R., Munson, D. A., Posencheg, M. A. & Ischiropoulos, H. Biological significance of nitric oxide-mediated protein modifications. Am. J. Physiol. Lung Cell. Mol. Physiol. 287, L262-L268 (2004).
39. Hill, B. G., Dranka, B. P., Bailey, S. M., Lancaster, J. R. Jr & Darley-Usmar, V. M. What part of NO don't you understand? Some answers to the cardinal questions in nitric oxide biology J. Biol. Chem. 285, 19699-19704 (2010).
40. Liu, X. et al. Diffusion-limited reaction of free nitric oxide with erythrocytes. J. Biol. Chem. 273, 18709-18713 (1998).
41. Hobbs, A. J. Soluble guanylate cyclase: the forgotten sibling. Trends Pharmacol. Sci. 18, 484-491 (1997).
42. Kojda, G. & Kottenberg, K. Regulation of basal myocardial function by NO. Cardiovasc. Res. 41, 514-523 (1999).
43. Castro, L. R., Schittl, J. & Fischmeister, R. Feedback control through cGMP-dependent protein kinase contributes to differential regulation and compartmentation of cGMP in rat cardiac myocytes. Circ. Res. 107, 1232-1240 (2010).
44. Gladwin, M. T. et al. Relative role of heme nitrosylation and β-cysteine 93 nitrosation in the transport and metabolism of nitric oxide by hemoglobin in the human circulation. Proc. Natl Acad. Sci. USA 97, 9943-9948 (2000).
45. Eich, R. F et al. Mechanism of NO-induced oxidation of myoglobin and hemoglobin. Biochemistry 35, 6976-6983 (1996).
46. Cleeter, M. W., Cooper, J. M., Darley-Usmar, V. M., Moncada, S. & Schapira, A. H. Reversible inhibition of cytochrome c oxidase, the terminal enzyme of the mitochondrial respiratory chain, by nitric oxide. Implications for neurodegenerative diseases. FEBS Lett. 345, 50-54 (1994).
47. Brown, G. C. & Cooper, C. E. Nanomolar concentrations of nitric oxide reversibly inhibit synaptosomal respiration by competing with oxygen at cytochrome oxidase. FEBS Lett. 356, 295-298 (1994).
48. Boveris, A., Costa, L. E., Poderoso, J. J., Carreras, M. C. & Cadenas, E. Regulation of mitochondrial respiration by oxygen and nitric oxide. Ann. NY Acad. Sci. 899, 121-135 (2000).
49. Hess, D. T., Matsumoto, A., Nudelman, R. & Stamler, J. S. S-nitrosylation: spectrum and specificity Nat. Cell Biol. 3, E46-E49 (2001).
50. Turko, I. V. & Murad, F Protein nitration in cardiovascular diseases. Pharmacol. Rev. 54, 619-634 (2002).
51. Stamler, J. S., Lamas, S. & Fang, F C. Nitrosylation: the prototypic redox-based signaling mechanism. Cell 106, 675-683 (2001).
52. Baker, P. R. et al. Fatty acid transduction of nitric oxide signaling: multiple nitrated unsaturated fatty acid derivatives exist in human blood and urine and serve as endogenous peroxisome proliferator-activated receptor ligands. J. Biol. Chem. 280, 42464-42475 (2005).
53. Sawa, T. et al. Protein S-guanylation by the biological signal 8-nitroguanosine 3', 5'-cyclic monophosphate. Nat. Chem. Biol. 3, 727-735 (2007).
54. Ito, C. et al. Endogenous nitrated nucleotide is a key mediator of autophagy and innate defense against bacteria. Mol. Cell 52, 794-804 (2013).
55. Fang, F C. Mechanisms of nitric oxide-related antimicrobial activity. J. Clin. Invest. 99, 2818-2825 (1997).
56. Schechter, A. N. & Gladwin, M. T. Hemoglobin and the paracrine and endocrine functions of nitric oxide. N. Engl. J. Med. 348, 1483-1485 (2003).
57. Azarov, I. et al. Nitric oxide scavenging by red blood cells as a function of hematocrit and oxygenation. J. Biol. Chem. 280, 39024-39032 (2005).
58. Straub, A. C. et al. Endothelial cell expression of haemoglobin a regulates nitric oxide signalling. Nature 491, 473-477 (2012).
59. Gladwin, M. T. & Kim-Shapiro, D. B. Vascular biology: nitric oxide caught in traffic. Nature 491, 344-345 (2012).
60. Fox-Robichaud, A. et al. Inhaled NO as a viable antiadhesive therapy for ischemia/reperfusion injury of distal microvascular beds. J. Clin. Invest. 101, 2497-2505 (1998).
61. Cannon, R. O. et al. Effects of inhaled nitric oxide on regional blood flow are consistent with intravascular nitric oxide delivery. J. Clin. Invest. 108, 279-287 (2001).
62. Jia, L., Bonaventura, C, Bonaventura, J. & Stamler, J. S. S-nitrosohaemoglobin: a dynamic activity of blood involved in vascular control. Nature 380, 221-226 (1996).
63. Chen, C. A. et al. S-glutathionylation uncouples eNOS and regulates its cellular and vascular function. Nature 468, 1115-1118 (2010).
64. Wu, F. et al. Nox2-dependent glutathionylation of endothelial NOS leads to uncoupled superoxide production and endothelial barrier dysfunction in acute lung injury. Am. J. Physiol. Lung Cell. Mol. Physiol. 307, L987-L997 (2014).
65. Wever, R. M., van Dam, T., van Rijn, H. J., de Groot, F. & Rabelink, T. J. Tetrahydrobiopterin regulates superoxide and nitric oxide generation by recombinant endothelial nitric oxide synthase. Biochem. Biophys. Res. Commun. 237, 340-344 (1997).
66. Yang, Z. & Ming, X. F. Arginase: the emerging therapeutic target for vascular oxidative stress and inflammation. Front. Immunol. 4, 149 (2013).
67. Stasch, J. P., Pacher, P. & Evgenov, O. V. Soluble guanylate cyclase as an emerging therapeutic target in cardiopulmonary disease. Circulation 123, 2263-2273 (2011).
68. Potoka, K. P. & Gladwin, M. T. Vasculopathy and pulmonary hypertension in sickle cell disease. Am. J. Physiol. Lung Cell. Mol. Physiol. 308, L314-L324 (2015).
69. Ignarro, L. J. Nitric oxide as a unique signaling molecule in the vascular system: a historical overview. J. Physiol. Pharmacol. 53, 503-514 (2002).
70. Rees, D. D., Palmer, R. M. & Moncada, S. Role of endothelium-derived nitric oxide in the regulation of blood pressure. Proc. Natl Acad. Sci. USA 86, 3375-3378 (1989).
71. Huang, P. L. et al. Hypertension in mice lacking the gene for endothelial nitric oxide synthase. Nature 377, 239-242 (1995).
72. Moncada, S. & Higgs, A. The l-arginine-nitric oxide pathway. N. Engl. J. Med. 329, 2002-2012 (1993).
73. Balligand, J. L., Kelly, R. A., Marsden, P. A., Smith, T. W. & Michel, T. Control of cardiac muscle cell function by an endogenous nitric oxide signaling system. Proc. Natl Acad. Sci. USA 90, 347-351 (1993).
74. Jumrussirikul, P. et al. Interaction between neuronal nitric oxide synthase and inhibitory G protein activity in heart rate regulation in conscious mice. J. Clin. Invest. 102, 1279-1285 (1998).
75. Takano, H. et al. Nitric oxide synthase is the mediator of late preconditioning against myocardial infarction in conscious rabbits. Circulation 98, 441-449 (1998).
76. Cohen, M. V. & Downey, J. M. Ischemic postconditioning: from receptor to end-effector. Antioxid. Redox Signal. 14, 821-831 (2011).
77. Seddon, M., Shah, A. M. & Casadei, B. Cardiomyocytes as effectors of nitric oxide signalling. Cardiovasc. Res. 75, 315-326 (2007).
78. Tang, L., Wang, H. & Ziolo, M. T. Targeting NOS as a therapeutic approach for heart failure. Pharmacol. Ther. 142, 306-315 (2014).
79. Xu, L., Eu, J. P., Meissner, G. & Stamler, J. S. Activation of the cardiac calcium release channel (ryanodine receptor) by poly-S-nitrosylation. Science 279, 234-237 (1998).
80. Jones, S. P. & Bolli, R. The ubiquitous role of nitric oxide in cardioprotection. J. Mol. Cell. Cardiol. 40, 16-23 (2006).
81. West, M. B. et al. Cardiac myocyte-specific expression of inducible nitric oxide synthase protects against ischemia/reperfusion injury by preventing mitochondrial permeability transition. Circulation 118, 1970-1978 (2008).
82. Sasaki, N., Sato, T., Ohler, A., O'Rourke, B. & Marban, E. Activation of mitochondrial ATP-dependent potassium channels by nitric oxide. Circulation 101, 439-445 (2000).
83. Ertracht, O., Malka, A., Atar, S. & Binah, O. The mitochondria as a target for cardioprotection in acute myocardial ischemia. Pharmacol. Ther. 142, 33-40 (2014).
84. Chouchani, E. T. et al. Cardioprotection by S-nitrosation of a cysteine switch on mitochondrial complex I. Nat. Med. 19, 753-759 (2013).
85. Shiva, S. et al. Nitrite augments tolerance to ischemia/ reperfusion injury via the modulation of mitochondrial electron transfer. J. Exp. Med. 204, 2089-2102 (2007).
86. Rassaf, T. et al. Circulating nitrite contributes to cardioprotection by remote ischemic preconditioning. Circ. Res. 114, 1601-1610 (2014).
87. Hataishi, R. et al. Inhaled nitric oxide decreases infarction size and improves left ventricular function in a murine model of myocardial ischemia-reperfusion injury. Am. J. Physiol. Heart Circ. Physiol. 291, H379-H384 (2006).
88. Lang, J. D. Jr. et al. Inhaled NO accelerates restoration of liver function in adults following orthotopic liver transplantation. J. Clin. Invest. 117, 2583-2591 (2007).
89. Lang, J. D. Jr. et al. A randomized clinical trial testing the anti-inflammatory effects of preemptive inhaled nitric oxide in human liver transplantation. PLoS ONE 9, e86053 (2014).
90. Wallace, J. L., Ignarro, L. J. & Fiorucci, S. Potential cardioprotective actions of no-releasing aspirin. Nat. Rev. Drug Discov. 1, 375-382 (2002).
91. Zacharowski, P. et al. The effects and metabolic fate of nitroflurbiprofen in healthy volunteers. Clin. Pharmacol. Ther. 76, 350-358 (2004).
92. Cavet, M. E., Vittitow, J. L., Impagnatiello, F., Ongini, E. & Bastia, E. Nitric oxide (NO): an emerging target for the treatment of glaucoma. Invest. Ophthalmol. Vis. Sci. 55, 5005-5015 (2014).
93. Miller, M. R. & Megson, I. L. Recent developments in nitric oxide donor drugs. Br. J. Pharmacol. 151, 305-321 (2007).
94. Tran, H. & Anand, S. S. Oral antiplatelet therapy in cerebrovascular disease, coronary artery disease, and peripheral arterial disease. JAMA 292, 1867-1874 (2004).
95. Anderson, R. A., Bundhoo, S. & James, P. E. A new mechanism of action of thienopyridine antiplatelet drugs - a role for gastric nitrosthiol metabolism? Atherosclerosis 237, 369-373 (2014).
96. Gilard, M. et al. Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, double-blind OCLA (Omeprazole CLopidogrel Aspirin) study. J. Am. Coll. Cardiol. 51, 256-260 (2008).
97. Bundhoo, S. S. et al. Direct vasoactive properties of thienopyridine-derived nitrosothiols. J. Cardiovasc. Pharmacol. 58, 550-558 (2011).
98. Cosby, K. et al. Nitrite reduction to nitric oxide by deoxyhemoglobin vasodilates the human circulation. Nat. Med. 9, 1498-1505 (2003).
99. Liu, C. et al. Mechanisms of human erythrocytic bioactivation of nitrite. J. Biol. Chem. 290, 1281-1294 (2015).
100. Hunter, C. J. et al. Inhaled nebulized nitrite is a hypoxia-sensitive NO-dependent selective pulmonary vasodilator. Nat. Med. 10, 1122-1127 (2004).
101. Webb, A. et al. Reduction of nitrite to nitric oxide during ischemia protects against myocardial ischemia- reperfusion damage. Proc. Natl Acad. Sci. USA 101, 13683-13688 (2004).
102. Duranski, M. R. et al. Cytoprotective effects of nitrite during in vivo ischemia-reperfusion of the heart and liver. J. Clin. Invest. 115, 1232-1240 (2005).
103. Hendgen-Cotta, U. B. et al. Nitrite reductase activity of myoglobin regulates respiration and cellular viability in myocardial ischemia-reperfusion injury. Proc. Natl Acad. Sci. USA 105, 10256-10261 (2008).
104. Rix, P. J. et al. Pharmacokinetics, pharmacodynamics, safety, and tolerability of nebulized sodium nitrite (AIR001) following repeat-dose inhalation in healthy subjects. Clin. Pharmacokinet. 54, 261-272 (2015).
105. Dejam, A. et al. Nitrite infusion in humans and nonhuman primates: endocrine effects, pharmacokinetics, and tolerance formation. Circulation 116, 1821-1831 (2007).
106. Mohler, E. R. et al. Sodium nitrite in patients with peripheral artery disease and diabetes mellitus: safety, walking distance and endothelial function. Vasc. Med. 19, 9-17 (2014).
107. Hunault, C. C., van Velzen, A. G., Sips, A. J., Schothorst, R. C. & Meulenbelt, J. Bioavailability of sodium nitrite from an aqueous solution in healthy adults. Toxicol. Lett. 190, 48-53 (2009).
108. Pluta, R. M. et al. Safety and feasibility of long-term intravenous sodium nitrite infusion in healthy volunteers. PLoS ONE 6, e14504 (2011).
109. Oldfield, E. H. et al. Safety and pharmacokinetics of sodium nitrite in patients with subarachnoid hemorrhage: a Phase IIA study. J. Neurosurg. 119, 634-641 (2013).
110. Siddiqi, N. et al. Intravenous sodium nitrite in acute ST-elevation myocardial infarction: a randomized controlled trial (NIAMI). Eur. Heart J. 35, 1255-1262 (2014).
111. Jones, D. A. et al. Randomized Phase 2 trial of intracoronary nitrite during acute myocardial infarction. Circ. Res. 116, 437-447 (2015).
112. Webb, A. J. et al. Acute blood pressure lowering, vasoprotective, and antiplatelet properties of dietary nitrate via bioconversion to nitrite. Hypertension 51, 784-790 (2008).
113. Omar, S. A., Artime, E. & Webb, A. J. A comparison of organic and inorganic nitrates/nitrites. Nitric Oxide 26, 229-240 (2012).
114. Carlstrom, M. et al. Dietary inorganic nitrate reverses features of metabolic syndrome in endothelial nitric oxide synthase-deficient mice. Proc. Natl Acad. Sci. USA 107, 17716-17720 (2010).
115. Carlstrom, M. et al. Dietary nitrate attenuates oxidative stress, prevents cardiac and renal injuries, and reduces blood pressure in salt-induced hypertension. Cardiovasc. Res. 89, 574-585 (2011).
116. Jadert, C. et al. Decreased leukocyte recruitment by inorganic nitrate and nitrite in microvascular inflammation and NSAID-induced intestinal injury. Free Radic. Biol. Med. 52, 683-692 (2012).
117. Bryan, N. S. et al. Dietary nitrite supplementation protects against myocardial ischemia-reperfusion injury. Proc. Natl Acad. Sci. USA 104, 19144-19149 (2007).
118. Hendgen-Cotta, U. B. et al. Dietary nitrate supplementation improves revascularization in chronic ischemia. Circulation 126, 1983-1992 (2012).
119. Govoni, M., Jansson, E. A., Weitzberg, E. & Lundberg, J. O. The increase in plasma nitrite after a dietary nitrate load is markedly attenuated by an antibacterial mouthwash. Nitric Oxide 19, 333-337 (2008).
120. Petersson, J. et al. Gastroprotective and blood pressure lowering effects of dietary nitrate are abolished by an antiseptic mouthwash. Free Radic. Biol. Med. 46, 1068-1075 (2009).
121. Gao, X. et al. NADPH oxidase in the renal microvasculature is a primary target for blood pressure-lowering effects by inorganic nitrate and nitrite. Hypertension 65, 161-170 (2015).
122. Lundberg, J. O., Weitzberg, E., Lundberg, J. M. & Alving, K. Intragastric nitric oxide production in humans: measurements in expelled air. Gut 35, 1543-1546 (1994).
123. Pinheiro, L. C. et al. Increase in gastric pH reduces hypotensive effect of oral sodium nitrite in rats. Free Radic. Biol. Med. 53, 701-709 (2012).
124. Ghebremariam, Y. T. et al. Unexpected effect of proton pump inhibitors: elevation of the cardiovascular risk factor asymmetric dimethylarginine. Circulation 128, 845-853 (2013).
125. Montenegro, M. F. & Lundberg, J. O. Letter by Montenegro and Lundberg regarding article, "Unexpected effect of proton pump inhibitors: elevation of the cardiovascular risk factor asymmetric dimethylarginine". Circulation 129, E426-E426 (2014).
126. Kapil, V. et al. Physiological role for nitrate-reducing oral bacteria in blood pressure control. Free Radic. Biol. Med. 55, 93-100 (2013).
127. Bondonno, C. P. et al. Antibacterial mouthwash blunts oral nitrate reduction and increases blood pressure in treated hypertensive men and women. Am. J. Hypertens. 28, 572-575 (2015).
128. O'Donnell, V. B. et al. Nitration of unsaturated fatty acids by nitric oxide-derived reactive nitrogen species peroxynitrite, nitrous acid, nitrogen dioxide, and nitronium ion. Chem. Res. Toxicol. 12, 83-92 (1999).
129. Trostchansky, A., Bonilla, L., Gonzalez-Perilli, L. & Rubbo, H. Nitro-fatty acids: formation, redox signaling, and therapeutic potential. Antioxid. Redox Signal. 19, 1257-1265 (2013).
130. Delmastro-Greenwood, M., Freeman, B. A. & Wendell, S. G. Redox-dependent anti-inflammatory signaling actions of unsaturated fatty acids. Annu. Rev. Physiol. 76, 79-105 (2014).
131. Nadtochiy, S. M. et al. Nitroalkenes confer acute cardioprotection via adenine nucleotide translocase 1. J. Biol. Chem. 287, 3573-3580 (2012).
132. Cole, M. P. et al. Nitro-fatty acid inhibition of neointima formation after endoluminal vessel injury. Circ. Res. 105, 965-972 (2009).
133. Rudolph, V. et al. Endogenous generation and protective effects of nitro-fatty acids in a murine model of focal cardiac ischaemia and reperfusion. Cardiovasc. Res. 85, 155-166 (2010).
134. Lim, D. G. et al. Nitrolinoleate, a nitric oxide-derived mediator of cell function: synthesis, characterization, and vasomotor activity. Proc. Natl Acad. Sci. USA 99, 15941-15946 (2002).
135. Rocha, B. S. et al. Intragastric nitration by dietary nitrite: implications for modulation of protein and lipid signaling. Free Radic. Biol. Med. 52, 693-698 (2012).
136. Rocha, B. S. et al. Pepsin is nitrated in the rat stomach, acquiring antiulcerogenic activity: a novel interaction between dietary nitrate and gut proteins. Free Radic. Biol. Med. 58, 26-34 (2013).
137. Charles, R. L. et al. Protection from hypertension in mice by the Mediterranean diet is mediated by nitro fatty acid inhibition of soluble epoxide hydrolase. Proc. Natl Acad. Sci. USA 111, 8167-8172 (2014).
138. Wu, G. & Morris, S. M. Jr. Arginine metabolism: nitric oxide and beyond. Biochem. J. 336, 1-17 (1998).
139. Schulman, S. P. et al. l-arginine therapy in acute myocardial infarction: the Vascular Interaction with Age in Myocardial Infarction (VINTAGE MI) randomized clinical trial. JAMA 295, 58-64 (2006).
140. Wilson, A. M., Harada, R., Nair, N., Balasubramanian, N. & Cooke, J. P. l-arginine supplementation in peripheral arterial disease: no benefit and possible harm. Circulation 116, 188-195 (2007).
141. Dong, J. Y. et al. Effect of oral l-arginine supplementation on blood pressure: a meta-analysis of randomized, double-blind, placebo-controlled trials. Am. Heart J. 162, 959-965 (2011).
142. Pernow, J. & Jung, C. Arginase as a potential target in the treatment of cardiovascular disease: reversal of arginine steal? Cardiovasc. Res. 98, 334-343 (2013).
143. Boger, R. H. The pharmacodynamics of l-arginine. J. Nutr. 137, 1650S-1655S (2007).
144. Solomonson, L. P., Flam, B. R., Pendleton, L. C., Goodwin, B. L. & Eichler, D. C. The caveolar nitric oxide synthase/arginine regeneration system for NO production in endothelial cells. J. Exp. Biol. 206, 2083-2087 (2003).
145. Schwedhelm, E. et al. Pharmacokinetic and pharmacodynamic properties of oral l-citrulline and l-arginine: impact on nitric oxide metabolism. Br. J. Clin. Pharmacol. 65, 51-59 (2008).
146. Li, H., Horke, S. & Forstermann, U. Vascular oxidative stress, nitric oxide and atherosclerosis. Atherosclerosis 237, 208-219 (2014).
147. Li, H. & Forstermann, U. Uncoupling of endothelial NO synthase in atherosclerosis and vascular disease. Curr. Opin. Pharmacol. 13, 161-167 (2013).
148. Drummond, G. R., Selemidis, S., Griendling, K. K. & Sobey, C. G. Combating oxidative stress in vascular disease: NADPH oxidases as therapeutic targets. Nat. Rev. Drug Discov. 10, 453-471 (2011).
149. Cosentino, F. et al. Chronic treatment with tetrahydrobiopterin reverses endothelial dysfunction and oxidative stress in hypercholesterolaemia. Heart 94, 487-492 (2008).
150. Cunnington, C. et al. Systemic and vascular oxidation limits the efficacy of oral tetrahydrobiopterin treatment in patients with coronary artery disease. Circulation 125, 1356-1366 (2012).
151. Morris, C. R. et al. Dysregulated arginine metabolism, hemolysis-associated pulmonary hypertension, and mortality in sickle cell disease. JAMA 294, 81-90 (2005).
152. Xu, W. et al. Increased arginase II and decreased NO synthesis in endothelial cells of patients with pulmonary arterial hypertension. FASEB J. 18, 1746-1748 (2004).
153. Tang, W. H., Wang, Z., Cho, L., Brennan, D. M. & Hazen, S. L. Diminished global arginine bioavailability and increased arginine catabolism as metabolic profile of increased cardiovascular risk. J. Am. Coll. Cardiol. 53, 2061-2067 (2009).
154. Tang, W. H. et al. Diminished global arginine bioavailability as a metabolic defect in chronic systolic heart failure. J. Card. Fail. 19, 87-93 (2013).
155. Jung, C., Gonon, A. T., Sjoquist, P. O., Lundberg, J. O. & Pernow, J. Arginase inhibition mediates cardioprotection during ischaemia-reperfusion. Cardiovasc. Res. 85, 147-154 (2010).
156. Gonon, A. T. et al. Local arginase inhibition during early reperfusion mediates cardioprotection via increased nitric oxide production. PLoS ONE 7, e42038 (2012).
157. Gronros, J. et al. Arginase inhibition restores in vivo coronary microvascular function in type 2 diabetic rats. Am. J. Physiol. Heart Circ. Physiol. 300, H1174-H1181 (2011).
158. Tratsiakovich, Y. et al. Arginase inhibition reduces infarct size via nitric oxide, protein kinase C epsilon and mitochondrial ATP-dependent K+ channels. Eur. J. Pharmacol. 712, 16-21 (2013).
159. Kleinbongard, P. et al. Red blood cells express a functional endothelial nitric oxide synthase. Blood 107, 2943-2951 (2006).
160. Yang, J., Gonon, A. T., Sjoquist, P. O., Lundberg, J. O. & Pernow, J. Arginase regulates red blood cell nitric oxide synthase and export of cardioprotective nitric oxide bioactivity. Proc. Natl Acad. Sci. USA 110, 15049-15054 (2013).
161. Shemyakin, A. et al. Arginase inhibition improves endothelial function in patients with coronary artery disease and type 2 diabetes mellitus. Circulation 126, 2943-2950 (2012).
162. Ashmore, T. et al. Dietary nitrate increases arginine availability and protects mitochondrial complex I and energetics in the hypoxic rat heart. J. Physiol. 592, 4715-4731 (2014).
163. Witte, M. B. & Barbul, A. Arginine physiology and its implication for wound healing. Wound Repair Regen. 11, 419-423 (2003).
164. Vallance, P. & Leiper, J. Cardiovascular biology of the asymmetric dimethylarginine:dimethylarginine dimethylaminohydrolase pathway. Arterioscler Thromb. Vasc. Biol. 24, 1023-1030 (2004).
165. Leiper, J. & Nandi, M. The therapeutic potential of targeting endogenous inhibitors of nitric oxide synthesis. Nat. Rev. Drug Discov. 10, 277-291 (2011).
166. Ridker, P. M. LDL cholesterol: controversies and future therapeutic directions. Lancet 384, 607-617 (2014).
167. Endo, A. The origin of the statins. Atheroscler. Suppl. 5, 125-130 (2004).
168. Davignon, J. Beneficial cardiovascular pleiotropic effects of statins. Circulation 109, III39-III43 (2004).
169. Laufs, U. & Liao, J. K. Post-transcriptional regulation of endothelial nitric oxide synthase mRNA stability by Rho GTPase. J. Biol. Chem. 273, 24266-24271 (1998).
170. Kureishi, Y et al. The HMG-CoA reductase inhibitor simvastatin activates the protein kinase Akt and promotes angiogenesis in normocholesterolemic animals. Nat. Med. 6, 1004-1010 (2000).
171. Kosmidou, I., Moore, J. P., Weber, M. & Searles, C. D. Statin treatment and 3' polyadenylation of eNOS mRNA. Arterioscler. Thromb. Vasc. Biol. 27, 2642-2649 (2007).
172. Feron, O., Dessy, C, Desager, J. P. & Balligand, J. L. Hydroxy-methylglutaryl-coenzyme A reductase inhibition promotes endothelial nitric oxide synthase activation through a decrease in caveolin abundance. Circulation 103, 113-118 (2001).
173. Antoniades, C. et al. Rapid, direct effects of statin treatment on arterial redox state and nitric oxide bioavailability in human atherosclerosis via tetrahydrobiopterin-mediated endothelial nitric oxide synthase coupling. Circulation 124, 335-345 (2011).
174. Cai, H., Griendling, K. K. & Harrison, D. G. The vascular NAD(P)H oxidases as therapeutic targets in cardiovascular diseases. Trends Pharmacol. Sci. 24, 471-478 (2003).
175. Ivashchenko, C. Y. et al. Regulation of the ADMA-DDAH system in endothelial cells: a novel mechanism for the sterol response element binding proteins, SREBP1c and -2. Am. J. Physiol. Heart Circ. Physiol. 298, H251-H258 (2010).
176. Behrendt, D. & Ganz, P. Endothelial function: from vascular biology to clinical applications. Am. J. Cardiol. 90, 40L-48L (2002).
177. Nussinovitch, U., de Carvalho, J. F., Pereira, R. M. & Shoenfeld, Y Glucocorticoids and the cardiovascular system: state of the art. Curr. Pharm. Des. 16, 3574-3585 (2010).
178. Hafezi-Moghadam, A. et al. Acute cardiovascular protective effects of corticosteroids are mediated by non-transcriptional activation of endothelial nitric oxide synthase. Nat. Med. 8, 473-479 (2002).
179. Perretti, M. & DAcquisto, F. Annexin A1 and glucocorticoids as effectors of the resolution of inflammation. Nat. Rev. Immunol. 9, 62-70 (2009).
180. Conti, V. et al. Adrenoreceptors and nitric oxide in the cardiovascular system. Front. Physiol. 4, 321 (2013).
181. 3-adrenoreceptors mediate nitric oxide-dependent vasorelaxation of coronary microvessels in response to the third-generation β-blocker nebivolol. Circulation 112, 1198-1205 (2005).
182. Okamoto, L. E. et al. Nebivolol, but not metoprolol, lowers blood pressure in nitric oxide-sensitive human hypertension. Hypertension 64, 1241-1247 (2014).
183. Schiffrin, E. L., Park, J. B., Intengan, H. D. & Touyz, R. M. Correction of arterial structure and endothelial dysfunction in human essential hypertension by the angiotensin receptor antagonist losartan. Circulation 101, 1653-1659 (2000).
184. Nguyen Dinh Cat, A., Montezano, A. C., Burger, D. & Touyz, R. M. Angiotensin II, NADPH oxidase, and redox signaling in the vasculature. Antioxid. Redox Signal. 19, 1110-1120 (2013).
185. Wenzel, P. et al. AT1-receptor blockade by telmisartan upregulates GTP-cyclohydrolase I and protects eNOS in diabetic rats. Free Radic. Biol. Med. 45, 619-626 (2008).
186. Satoh, M. et al. Angiotensin II type 1 receptor blocker ameliorates uncoupled endothelial nitric oxide synthase in rats with experimental diabetic nephropathy. Nephrol. Dial. Transplant. 23, 3806-3813 (2008).
187. Oak, J. H. & Cai, H. Attenuation of angiotensin II signaling recouples eNOS and inhibits nonendothelial NOX activity in diabetic mice. Diabetes 56, 118-126 (2007).
188. Knorr, M. et al. Nitroglycerin-induced endothelial dysfunction and tolerance involve adverse phosphorylation and S-glutathionylation of endothelial nitric oxide synthase: beneficial effects of therapy with the AT1 receptor blocker telmisartan. Arterioscler. Thromb. Vasc. Biol. 31, 2223-2231 (2011).
189. Al Ghouleh, I. et al. Oxidases and peroxidases in cardiovascular and lung disease: new concepts in reactive oxygen species signaling. Free Radic. Biol. Med. 51, 1271-1288 (2011).
190. Bedard, K. & Krause, K. H. The NOX family of ROS-generating NADPH oxidases: physiology and pathophysiology. Physiol. Rev. 87, 245-313 (2007).
191. Gutteridge, J. M. & Halliwell, B. Antioxidants: molecules, medicines, and myths. Biochem. Biophys. Res. Commun. 393, 561-564 (2010).
192. Ristow, M. et al. Antioxidants prevent health-promoting effects of physical exercise in humans. Proc. Natl Acad. Sci. USA 106, 8665-8670 (2009).
193. Altenhofer, S., Radermacher, K. A., Kleikers, P. W., Wingler, K. & Schmidt, H. H. Evolution of NADPH oxidase inhibitors: selectivity and mechanisms for target engagement. Antioxid. Redox Signal. http://dx.doi.org/10.1089/ars.2013.5814 (2014).
194. Ranayhossaini, D. J. et al. Selective recapitulation of conserved and nonconserved regions of putative NOXA1 protein activation domain confers isoform-specific inhibition of Nox1 oxidase and attenuation of endothelial cell migration. J. Biol. Chem. 288, 36437-36450 (2013).
195. Cifuentes-Pagano, E., Meijles, D. N. & Pagano, P. J. The quest for selective nox inhibitors and therapeutics: challenges, triumphs and pitfalls. Antioxid. Redox Signal. 20, 2741-2754 (2014).
196. Bender, A. T. & Beavo, J. A. Cyclic nucleotide phosphodiesterases: molecular regulation to clinical use. Pharmacol. Rev. 58, 488-520 (2006).
197. Goldstein, I. et al. Oral sildenafil in the treatment of erectile dysfunction. N. Engl. J. Med. 338, 1397-1404 (1998).
198. Michelakis, E. et al. Oral sildenafil is an effective and specific pulmonary vasodilator in patients with pulmonary arterial hypertension: comparison with inhaled nitric oxide. Circulation 105, 2398-2403 (2002).
199. Salloum, F., Yin, C., Xi, L. & Kukreja, R. C. Sildenafil induces delayed preconditioning through inducible nitric oxide synthase-dependent pathway in mouse heart. Circ. Res. 92, 595-597 (2003).
200. Thadani, U. et al. The effect of vardenafil, a potent and highly selective phosphodiesterase-5 inhibitor for the treatment of erectile dysfunction, on the cardiovascular response to exercise in patients with coronary artery disease. J. Am. Coll. Cardiol. 40, 2006-2012 (2002).
201. Senthilkumar, A. et al. Sildenafil promotes ischemia-induced angiogenesis through a PKG-dependent pathway. Arterioscler. Thromb. Vasc. Biol. 27, 1947-1954 (2007).
202. Fisher, P. W., Salloum, F., Das, A., Hyder, H. & Kukreja, R. C. Phosphodiesterase-5 inhibition with sildenafil attenuates cardiomyocyte apoptosis and left ventricular dysfunction in a chronic model of doxorubicin cardiotoxicity. Circulation 111, 1601-1610 (2005).
203. Roustit, M., Hellmann, M., Cracowski, C., Blaise, S. & Cracowski, J. L. Sildenafil increases digital skin blood flow during all phases of local cooling in primary Raynaud's phenomenon. Clin. Pharmacol. Ther. 91, 813-819 (2012).
204. Lukowski, R., Krieg, T., Rybalkin, S. D., Beavo, J. & Hofmann, F. Turning on cGMP-dependent pathways to treat cardiac dysfunctions: boom, bust, and beyond. Trends Pharmacol. Sci. 35, 404-413 (2014).
205. Ghofrani, H. A. et al. Riociguat for the treatment of pulmonary arterial hypertension. N. Engl. J. Med. 369, 330-340 (2013).
206. Ghofrani, H. A. et al. Riociguat for the treatment of chronic thromboembolic pulmonary hypertension. N. Engl. J. Med. 369, 319-329 (2013).
207. Follmann, M. et al. The chemistry and biology of soluble guanylate cyclase stimulators and activators. Angew. Chem. Int. Ed Engl. 52, 9442-9462 (2013).
208. Ko, F. N., Wu, C. C., Kuo, S. C., Lee, F. Y. & Teng, C. M. YC-1, a novel activator of platelet guanylate cyclase. Blood 84, 4226-4233 (1994).
209. Baliga, R. S., MacAllister, R. J. & Hobbs, A. J. New perspectives for the treatment of pulmonary hypertension. Br. J. Pharmacol. 163, 125-140 (2011).
210. Boerrigter, G. et al. Cardiorenal and humoral properties of a novel direct soluble guanylate cyclase stimulator BAY 41-2272 in experimental congestive heart failure. Circulation 107, 686-689 (2003).
211. Stasch, J. P., Dembowsky, K., Perzborn, E., Stahl, E. & Schramm, M. Cardiovascular actions of a novel NO-independent guanylyl cyclase stimulator, BAY 41-8543: in vivo studies. Br. J. Pharmacol. 135, 344-355 (2002).
212. Ahluwalia, A. et al. Antiinflammatory activity of soluble guanylate cyclase: cGMP-dependent down-regulation of P-selectin expression and leukocyte recruitment. Proc. Natl Acad. Sci. USA 101, 1386-1391 (2004).
213. Raat, N. J. et al. Direct sGC activation bypasses NO scavenging reactions of intravascular free oxy-hemoglobin and limits vasoconstriction. Antioxid. Redox Signal. 19, 2232-2243 (2013).
214. Baliga, R. S., Macallister, R. J. & Hobbs, A. J. Vasoactive peptides and the pathogenesis of pulmonary hypertension: role and potential therapeutic application. Handb. Exp. Pharmacol. 218, 477-511 (2013).
215. Baliga, R. S. et al. Synergy between natriuretic peptides and phosphodiesterase 5 inhibitors ameliorates pulmonary arterial hypertension. Am. J. Respir. Crit. Care Med. 178, 861-869 (2008).
216. Scalbert, A., Johnson, I. T. & Saltmarsh, M. Polyphenols: antioxidants and beyond. Am J. Clin. Nutr. 81, 215S-217S (2005).
217. Laurent, C. et al. Polyphenols decreased liver NADPH oxidase activity, increased muscle mitochondrial biogenesis and decreased gastrocnemius age-dependent autophagy in aged rats. Free Radic. Res. 46, 1140-1149 (2012).
218. Schewe, T., Steffen, Y. & Sies, H. How do dietary flavanols improve vascular function? A position paper. Arch. Biochem. Biophys. 476, 102-106 (2008).
219. Anter, E. et al. Activation of endothelial nitric-oxide synthase by the p38 MAPK in response to black tea polyphenols. J. Biol. Chem. 279, 46637-46643 (2004).
220. Schroeter, H. et al. (-)-epicatechin mediates beneficial effects of flavanol-rich cocoa on vascular function in humans. Proc. Natl Acad. Sci. USA 103, 1024-1029 (2006).
221. Balzer, J. et al. Sustained benefits in vascular function through flavanol-containing cocoa in medicated diabetic patients: a double-masked, randomized, controlled trial. J. Am. Coll. Cardiol. 51, 2141-2149 (2008).
222. Desideri, G. et al. Benefits in cognitive function, blood pressure, and insulin resistance through cocoa flavanol consumption in elderly subjects with mild cognitive impairment: the Cocoa, Cognition, and Aging (CoCoA) study. Hypertension 60, 794-801 (2012).
223. Heiss, C., Keen, C. L. & Kelm, M. Flavanols and cardiovascular disease prevention. Eur. Heart J. 31, 2583-2592 (2010).
224. Chiva-Blanch, G. et al. Dealcoholized red wine decreases systolic and diastolic blood pressure and increases plasma nitric oxide. Circ. Res. 111, 1065-1068 (2012).
225. Rocha, B. S. et al. Dietary nitrite in nitric oxide biology: a redox interplay with implications for pathophysiology and therapeutics. Curr. Drug Targets 12, 1351-1363 (2011).
226. Gago, B., Lundberg, J. O., Barbosa, R. M. & Laranjinha, J. Red wine-dependent reduction of nitrite to nitric oxide in the stomach. Free Radic. Biol. Med. 43, 1233-1242 (2007).
227. Rodriguez-Mateos, A. et al. Interactions between cocoa flavanols and inorganic nitrate: additive effects on endothelial function at dietary achievable amounts. Free Radic. Biol. Med. 80, 121-128 (2014).
228. Lee, S. Y. et al. The reaction of flavanols with nitrous acid protects against N-nitrosamine formation and leads to the formation of nitroso derivatives which inhibit cancer cell growth. Free Radic. Biol. Med. 40, 323-334 (2006).
229. Lucas, D. L., Brown, R. A., Wassef, M. & Giles, T. D. Alcohol and the cardiovascular system: research challenges and opportunities. J. Am. Coll. Cardiol. 45, 1916-1924 (2005).
230. Deng, X. S. & Deitrich, R. A. Ethanol metabolism and effects: nitric oxide and its interaction. Curr. Clin. Pharmacol. 2, 145-153 (2007).
231. Kokkinos, P. & Myers, J. Exercise and physical activity: clinical outcomes and applications. Circulation 122, 1637-1648 (2010).
232. Di Francescomarino, S., Sciartilli, A., Di Valerio, V., Di Baldassarre, A. & Gallina, S. The effect of physical exercise on endothelial function. Sports Med. 39, 797-812 (2009).
233. Charakida, M., Masi, S., Luscher, T. F., Kastelein, J. J. & Deanfield, J. E. Assessment of atherosclerosis: the role of flow-mediated dilatation. Eur. Heart J. 31, 2854-2861 (2010).
234. Hambrecht, R. et al. Regular physical activity improves endothelial function in patients with coronary artery disease by increasing phosphorylation of endothelial nitric oxide synthase. Circulation 107, 3152-3158 (2003).
235. Laufs, U. et al. Physical training increases endothelial progenitor cells, inhibits neointima formation, and enhances angiogenesis. Circulation 109, 220-226 (2004).
236. Iwakura, A. et al. Estrogen-mediated, endothelial nitric oxide synthase-dependent mobilization of bone marrow-derived endothelial progenitor cells contributes to reendothelialization after arterial injury. Circulation 108, 3115-3121 (2003).
237. Lauer, T. et al. Age-dependent endothelial dysfunction is associated with failure to increase plasma nitrite in response to exercise. Basic Res. Cardiol. 103, 291-297 (2008).
238. Jungersten, L., Ambring, A., Wall, B. & Wennmalm, A. Both physical fitness and acute exercise regulate nitric oxide formation in healthy humans. J. Appl. Physiol. 82, 760-764 (1997).
239. Rassaf, T. et al. Vascular formation of nitrite after exercise is abolished in patients with cardiovascular risk factors and coronary artery disease. J. Am. Coll. Cardiol. 55, 1502-1503 (2010).
240. Kelly, J. et al. Dietary nitrate supplementation reduces the oxygen cost of exercise in healthy older adults. Med. Sci. Sports Exercise 44, 443 (2012).
241. Bailey, S. J. et al. Dietary nitrate supplementation enhances muscle contractile efficiency during knee-extensor exercise in humans. J. Appl. Physiol. 109, 943-943 (2010).
242. Larsen, F. J., Weitzberg, E., Lundberg, J. O. & Ekblom, B. Effects of dietary nitrate on oxygen cost during exercise. Acta Physiol. 191, 59-66 (2007).
243. Larsen, F. J., Weitzberg, E., Lundberg, J. O. & Ekblom, B. Dietary nitrate reduces maximal oxygen consumption while maintaining work performance at maximal exercise. Free Radic. Biol. Med. 48, 342-347 (2009).
244. Kenjale, A. A. et al. Dietary nitrate supplementation enhances exercise performance in peripheral arterial disease. J. Appl. Physiol. 110, 1582-1591 (2011).
245. Larsen, F. J., Schiffer, T. A., Weitzberg, E. & Lundberg, J. O. Regulation of mitochondrial function and energetics by reactive nitrogen oxides. Free Radic. Biol. Med. 53, 1919-1928 (2012).
246. Larsen, F. J. et al. Dietary inorganic nitrate improves mitochondrial efficiency in humans. Cell. Metab. 13, 149-159 (2011).
247. i and contractile force in mouse fast-twitch muscle. J. Physiol. 590, 3575-3583 (2012).
248. Ferguson, S. K. et al. Impact of dietary nitrate supplementation via beetroot juice on exercising muscle vascular control in rats. J. Physiol. 591, 547-557 (2013).
249. Zamani, P. et al. The effect of inorganic nitrate on exercise capacity in heart failure with preserved ejection fraction. Circulation 131, 371-380 (2014).
250. Berry, M. J. et al. Dietary nitrate supplementation improves exercise performance and decreases blood pressure in COPD patients. Nitric Oxide 48, 22-30 (2014).
251. Dellinger, R. P. et al. Effects of inhaled nitric oxide in patients with acute respiratory distress syndrome: results of a randomized phase II trial. Inhaled nitric oxide in ARDS study group. Crit. Care Med. 26, 15-23 (1998).
252. Lopez, A. et al. Multiple-center, randomized, placebo-controlled, double-blind study of the nitric oxide synthase inhibitor 546C88: effect on survival in patients with septic shock. Crit. Care Med. 32, 21-30 (2004).
253. Petros, A. et al. Effects of a nitric oxide synthase inhibitor in humans with septic shock. Cardiovasc. Res. 28, 34-39 (1994).
254. Schulz, E. et al. Functional and biochemical analysis of endothelial (dys)function and NO/cGMP signaling in human blood vessels with and without nitroglycerin pretreatment. Circulation 105, 1170-1175 (2002).
255. Tannenbaum, S. R. & Correa, P. Nitrate and gastric cancer risks. Nature 317, 675-676 (1985).
256. Tannenbaum, S. R., Sisnkey, A. J., Weisman, M. & Bishop, W. Nitrite in human saliva. Its possible relationship to nitrosamine formation. J. Natl Cancer Inst. 53, 79-84 (1974).
257. Bryan, N. S., Alexander, D. D., Coughlin, J. R., Milkowski, A. L. & Boffetta, P. Ingested nitrate and nitrite and stomach cancer risk: an updated review. Food Chem. Toxicol. 50, 3646-3665 (2012).
258. Lauer, T. et al. Plasma nitrite rather than nitrate reflects regional endothelial nitric oxide synthase activity but lacks intrinsic vasodilator action. Proc. Natl Acad. Sci. USA 98, 12814-12819 (2001).
259. Zweier, J. L., Wang, P., Samouilov, A. & Kuppusamy, P. Enzyme-independent formation of nitric oxide in biological tissues. Nat. Med. 1, 804-809 (1995).
260. Benjamin, N. et al. Stomach NO synthesis. Nature 368, 502 (1994).
261. Ghosh, S. M. et al. Enhanced vasodilator activity of nitrite in hypertension: critical role for erythrocytic xanthine oxidoreductase and translational potential. Hypertension 61, 1091-1102 (2013).
262. Richardson, G. et al. The ingestion of inorganic nitrate increases gastric S-nitrosothiol levels and inhibits platelet function in humans. Nitric Oxide 7, 24-29 (2002).
263. Heiss, C. et al. Dietary inorganic nitrate mobilizes circulating angiogenic cells. Free Radic. Biol. Med. 52, 1767-1772 (2012).
264. Kapil, V., Khambata, R. S., Robertson, A., Caulfield, M. J. & Ahluwalia, A. Dietary nitrate provides sustained blood pressure lowering in hypertensive patients: a randomized, phase 2, double-blind, placebo-controlled study. Hypertension 65, 320-327 (2015).
265. Appel, L. J. et al. A clinical trial of the effects of dietary patterns on blood pressure. DASH Collaborative Research Group. N. Engl. J. Med. 336, 1117-1124 (1997).